^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

APOBEC3H (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H)

i
Other names: APOBEC3H, Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H, ARP10, Apolipoprotein B MRNA Editing Enzyme, Catalytic Polypeptide-Like 3H, DNA DC->DU-Editing Enzyme APOBEC-3H, APOBEC-Related Protein 10, ARP-10, A3H, Apolipoprotein B MRNA-Editing Enzyme Catalytic Polypeptide-Like 3H
Associations
Trials
12d
Differential effects on tumor progression by APOBEC3A, APOBEC3B, and APOBEC3H Haplotype I in a breast cancer mouse xenograft model. (PubMed, Front Genet)
Consistent with tumor data, RNA-seq showed upregulation of tumor enhancing pathways only in cells that enhanced tumor progression. The results indicate that in a breast cancer xenograft model, APOBEC3A and APOBEC3H Haplotype I are more likely to contribute to enhanced tumor progression than APOBEC3B.
Preclinical • Journal
|
APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A) • APOBEC3H (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H)
3ms
Genomic characterization of host gene alterations in Theileria annulata-transformed leukocytes. (PubMed, Commun Biol)
Functional studies revealed that inhibition of the mutated oncogene ROS1 using crizotinib induces death in infected leukocytes, confirming its role in transformation...Our findings provide new insights into how T. annulata reprograms host cells through genomic instability and mutations, identifying ROS1 and TP53 as critical targets for therapeutic intervention. This work advances understanding of parasite-induced oncogenic transformation and offers pathways for future research.
Journal
|
TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • BAP1 (BRCA1 Associated Protein 1) • KMT2C (Lysine Methyltransferase 2C) • NOTCH2 (Notch 2) • FLT4 (Fms-related tyrosine kinase 4) • BARD1 (BRCA1 Associated RING Domain 1) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A) • DAXX (Death-domain associated protein) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • APOBEC3H (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H)
|
TP53 mutation
|
Xalkori (crizotinib)
11ms
Comprehensive Analysis of Roles of APOBEC3 Gene Family in Clear Cell Renal Cell Carcinoma. (PubMed, Arch Esp Urol)
These study findings suggest that APOBEC3 genes are commonly overexpressed in ccRCC, and their expression levels are associated with poor prognosis in ccRCC, somatic gene mutations, cancer immunomodulation, and immune cell infiltration levels in the tumor microenvironment.
Journal
|
PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOB (Apolipoprotein B) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A) • APOBEC3G (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3G) • APOBEC3H (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H)
|
VHL mutation
over1year
Comparative Molecular Docking of Apigenin and Luteolin versus Conventional Ligands for TP-53, pRb, APOBEC3H, and HPV-16 E6: Potential Clinical Applications in Preventing Gynecological Malignancies. (PubMed, Curr Issues Mol Biol)
A conversion formula was applied to translate these protein-protein interaction energies to a comparable scale for non-protein interactions, further underscoring the superior binding potential of apigenin and luteolin. These findings highlight the therapeutic promise of these natural compounds in preventing HPV-16-induced oncogenesis, warranting further experimental validation for clinical applications.
Journal
|
APOBEC3H (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H)
over1year
The cytidine deaminase APOBEC3C has unique sequence and genome feature preferences. (PubMed, Genetics)
Surprisingly, APOBEC3C lacks the bias for the lagging strand of DNA replication that is seen for APOBEC3A and APOBEC3B. The unique preferences of APOBEC3C constitute a mutation profile that will be useful in defining sites of APOBEC3C mutagenesis in human genomes.
Journal
|
APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A) • APOBEC3H (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H)
almost2years
Protein interaction map of APOBEC3 enzyme family reveals deamination-independent role in cellular function. (PubMed, Mol Cell Proteomics)
Altogether, the results uncover novel functions and interactions of the APOBEC3 family and suggest they may have fundamental roles in cellular RNA biology, their protein-protein interactions are not redundant, and there are protein-protein interactions with tumor suppressors, suggesting a role in cancer biology. Data are available via ProteomeXchange with identifier PXD044275.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOBEC3G (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3G) • APOBEC3H (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H)
2years
Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer. (PubMed, PLoS Genet)
The human cell line, HAP1, is engineered to express the thymidine kinase (TK) gene of HSV-1, which confers sensitivity to ganciclovir...Although the vast majority of APOBEC3A- and APOBEC3B-induced single base substitution mutations occur outside of predicted chromosomal DNA hairpin structures, whole genome sequence analyses and supporting biochemical studies also indicate that both enzymes are capable of deaminating the single-stranded loop regions of DNA hairpins at elevated rates. These studies combine to help resolve a long-standing etiologic debate on the source of APOBEC3 signature mutations in cancer and indicate that future diagnostic and therapeutic efforts should focus on both APOBEC3A and APOBEC3B.
Preclinical • Journal
|
APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A) • APOBEC3H (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H)
over2years
Mutational impact of APOBEC3A and APOBEC3B in a human cell line (SABCS 2023)
Signature comparisons with breast tumor whole genome sequences indicate that most malignancies manifest intermediate percentages of APOBEC3 signature mutations in YTCW motifs, mostly between 50 and 70%, suggesting that both enzymes are contributing in a combinatorial manner to the overall mutation landscape. These studies combine to help resolve a long-standing etiologic debate on the source of APOBEC3 signature mutations in cancer and indicate that future diagnostic and therapeutic efforts should focus on both enzymes.
Preclinical
|
APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A) • APOBEC3H (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H)
almost3years
Oncogenic Merkel Cell Polyomavirus T Antigen Truncating Mutations are Mediated by APOBEC3 Activity in Merkel Cell Carcinoma. (PubMed, Cancer Res Commun)
We further reveal an expression pattern of APOBECs in a large Finnish MCC sample cohort. Thus, the findings presented here suggest a molecular mechanism underlying an aggressive carcinoma with poor prognosis.
Journal
|
APOBEC3G (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3G) • APOBEC3H (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H)